secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023226
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara gets positive CHMP opinion for Ebvallo; Q3 net loss $84.1M
----------------------------------------------------------------

- CHMP positive opinion for Ebvallo in EBV+ PTLD; EC approval expected by end 2022.
- Cash $265.4M; expects operating runway into Q1 2024 with Pierre Fabre milestone.
- Q3 net loss $84.1M ($0.82/diluted share) vs $84.7M ($0.90) YoY; R&D $70.2M.
- ATA188 MRI data show less brain atrophy, potential remyelination in progressive MS patients with CDI.
- Tab-cel safety consistent; ORR 51.2% in Phase 3 ALLELE; seeking US commercialization partner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/0000950170-22-023226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017022023226/atra-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer